Managed Healthcare Executive April 30, 2024
In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium, talks about whether or not she favors ending interchangeability designation for biosimilars.
Lockhart spoke about biosimilars at an Asembia 2024 session yesterday but was interviewed earlier this month...